Description
Betrecep 5 mg contains Tofacitinib, a targeted small-molecule medication that inhibits the Janus kinase (JAK) signaling pathway. It is commonly prescribed in autoimmune and inflammatory diseases when patients do not respond adequately to conventional therapies.
🔬 Mechanism of Action
Tofacitinib selectively inhibits JAK1 and JAK3 enzymes, which play an important role in immune cell signaling and inflammation. By blocking these pathways, Betrecep 5 mg:
- Reduces inflammatory cytokine activity
- Decreases immune system overactivation
- Helps control symptoms of autoimmune diseases
💊 Indications
Betrecep 5 mg is indicated for:
- Moderate to Severe Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PsA)
- Moderate to Severe Ulcerative Colitis (UC)
It may be used as monotherapy or in combination with certain disease-modifying antirheumatic drugs (DMARDs).
📌 Key Features of Betrecep 5 mg
- Strength: 5 mg
- Dosage Form: Oral tablet
- Therapeutic Class: Janus Kinase (JAK) Inhibitor
- Administration: Taken orally, typically twice daily as prescribed
- Monitoring: Regular blood counts, liver function tests, and lipid profile monitoring recommended
⚕️ Benefits of Tofacitinib
- Targeted therapy for autoimmune diseases
- Helps reduce joint pain and inflammation
- Improves physical function and quality of life
- Convenient oral administration
⚠️ Precautions
- Increased risk of infections, including serious infections
- Possible increase in cholesterol levels
- Risk of blood clots and cardiovascular events in certain patients
- Regular monitoring required during treatment
- Use strictly under physician supervision
Betrecep 5 mg (Tofacitinib Tablets) is an effective targeted therapy for autoimmune inflammatory diseases, helping control immune system activity and improve patient outcomes when used under medical supervision.
